We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Final analysis from the phase-IIIb STASEY study, including data from 193 people with haemophilia A, further supports the benefit/risk profile of Hemlibra, with no new safety signals identified.